Phys Vivas · renal
Renal Cell Carcinoma AND Urothelial Malignancy — Viva Defence
DCE viva defence for Renal Cell Carcinoma AND Urothelial Malignancy.
On this page
Study tools
Target exams
Renal Cell Carcinoma AND Urothelial Malignancy Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Renal Cell Carcinoma AND Urothelial Malignancy. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
References8ShowHide
- [1]Chen YS, Yu CC, Chang R, Wu SH, et al. Efficacy of checkpoint inhibitors in genitourinary cancers with advanced chronic kidney disease Cancer Immunol Immunother, 2026.PMID 42426360
- [2]Petrelli F, Colombo Zefinetti L, D'Alessio A, Dottorini L, et al. Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings Curr Oncol Rep, 2026.PMID 42406187
- [3]Zhang Y, Wu G, Sun F, Wang B, et al. Radiomics and deep learning in upper tract urothelial carcinoma: advancing preoperative risk stratification and clinical decision-making Front Oncol, 2026.PMID 42404222
- [4]Jost LM, Duwe G, Kauth V, Höfner T, et al. [Artificial intelligence as decision support tool in urological oncology: current evidence and challenges] Urologie, 2026.PMID 42126599
- [5]Inoue S, Tsuboi I, Miszczyk M, Miyajima K, et al. Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis JAMA Netw Open, 2026.PMID 42084869
- [6]Maráz A, Koroncziová K, Rozsvai T [Immunotherapy for urological cancers in 2025] Magy Onkol, 2025.PMID 41385769
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922